Table 1.

Demographic, clinical and microbiological characteristics of CM patients

Variable	Patient 1	Patient 2
Sex	Female	Female
Age	64	56
Time after transplant at the admission	15 months	17 months
Duration of symptoms before diagnosisa	21 days	14 days
Immunosuppressive therapy	PR, MF, TC	PR, MF, TC
CSFb
Leukocytes/µL)	263 (98% MN)	31 (90% MN)
Glucose (mg/dL)	33	34
Proteins (mg/dL)	221,8	66,1
Initial anti-infective empirical therapy	Acyclovir (350 mg/24 h), ceftriaxone (2 g/12 h), antituberculous drugs	Ganciclovir (90 mg/24h)
Initial immunosuppressive therapy adjustment (type and time)	MF suspension at the admission TC suspension 1 week after admission	MF suspension at the admission TC dose decrease 5 days after admission
Initial cultures and microbiological results	CSF culture and NAAT negative, BC negative	CSF culture and NAAT positive
First positive microbiological test (time)	NAAT (CSF) (1 week after admission)	Gram and India ink staining/NAAT (CSF) (5 days after admission)
Antifungal therapy	Amphotericin B (250 mg/24 h), fluconazole (200 mg/12 h)	Amphotericin B (150 mg/24 h), fluconazole (200 mg/12h)
Time delay of adequate antifungal therapyc	7 days	5 days
Last immunosuppressive therapy	TC (0,75mg/24 h) PR (25 mg/24 h)	PR (5mg/24 h)
Weekly evolution of CMV viral load (cop/mL)c	91-420-3060-1024	208-158-317-52

PR: prednisone; MF: mycophenolate; TC: tacrolimus; CSF: cerebrospinal fluid; BC: blood culture; NAAT: nucleic-acid amplification tests; MN: mononuclear

aFrom the beginning of symptoms; ^bFirst lumbar punction; ^cFrom admission